{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:18:55Z","timestamp":1788153535404,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radiation therapy is key for lung cancer, but data on unplanned interruptions remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study investigated patterns, risk factors, and clinical impacts of radiotherapy interruptions in lung cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study enrolled 230 lung cancer patients undergoing radiotherapy (Jan 2020\u2010Dec 2022). After exclusion, 226 patients were analyzed and stratified into interrupted and non-interrupted groups by unplanned radiotherapy interruptions (\u22651-day pause, excluding scheduled breaks). Patterns and causes of interruptions were documented in detail. Early oncological response, treatment completion, acute toxicities, progression-free survival (PFS), and overall survival (OS) were monitored at 6 months post-radiotherapy. Multivariable linear regression identified interruption risk factors, while Cox regression and Kaplan\u2013Meier analysis with log-rank test evaluated survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 226 lung cancer patients were enrolled, 79 (34.96%) of whom had at least one treatment interruption, with a median duration of 5 days and 1 episode. Most interruptions occurred in the middle third of radiotherapy (60.76%), mainly caused by treatment-related toxicities (49.37%) and patient-related factors (27.85%). Multivariable linear regression showed that performance status (PS) score 2\u20133, stage III\u2013IV and tumor volume \u226550 cm\u00b3 remained significantly associated with radiotherapy interruption after adjustment for potential confounders (all P&amp;lt;0.05). The interrupted group had poorer compliance, lower overall response rate (ORR) and disease control rate (DCR), higher acute toxicities. Unadjusted Kaplan-Meier analysis showed worse 6-month PFS and OS in the interrupted group, and this association persisted in multivariable-adjusted Cox regression after controlling for PS score, tumor stage, tumor volume, treatment regimen, and radiotherapy modality (all P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Radiotherapy interruption is common in lung cancer patients, mainly caused by toxicity. It impairs treatment efficacy and survival, requiring individualized management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1894291","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:34Z","timestamp":1788150574000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns, causes, and clinical impact of treatment interruption on early outcomes in patients receiving radiotherapy for lung cancer: a retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Lifa","family":"Su","sequence":"first","affiliation":[{"name":"Department of Tumor Center, Chongqing University Three Gorges Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longbin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Tumor Center, Chongqing University Three Gorges Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Tumor Center, Chongqing University Three Gorges Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Tumor Center, Chongqing University Three Gorges Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Tumor Center, Chongqing University Three Gorges Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168661","article-title":"Current and future development in lung cancer diagnosis","volume":"22","author":"Nooreldeen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052049","article-title":"Lung cancer-epidemiology, pathogenesis, treatment and molecular aspect (review of literature)","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.17992\/lbl.2022.01.671","article-title":"Advances in lung cancer diagnosis and treatment - a review","volume":"108","author":"Harethardottir","year":"2022","journal-title":"Laeknabladid"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_52_21","article-title":"Evolving trends in lung cancer: epidemiology, diagnosis, and management","volume":"59","author":"Deshpand","year":"2022","journal-title":"Indian J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3089","article-title":"Stereotactic vs hypofractionated radiotherapy for inoperable stage I non-small cell lung cancer: the LUSTRE phase 3 randomized clinical trial","volume":"10","author":"Swaminath","year":"2024","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-26-518252","article-title":"State-of-the-art advances and management of unresectable locally advanced (stage III) non\u2013small cell lung cancer","volume":"46","author":"Desai","year":"2026","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111621","article-title":"Immune checkpoints inhibitors and SRS\/SBRT synergy in metastatic non-small-cell lung cancer and melanoma: a systematic review","volume":"22","author":"Rodriguez Pla","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010008","article-title":"Stereotactic body radiotherapy (SBRT) in very limited-stage small cell lung cancer (VLS-SCLC)","volume":"30","author":"Mercier","year":"2022","journal-title":"Curr Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01857-3","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of radiotherapy to block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","article-title":"UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy","volume":"34","author":"Diez","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00215-7","article-title":"Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial","volume":"12","author":"Zhao","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107281","article-title":"Stereotactic body radiotherapy for ultra-central lung tumors: a systematic review and meta-analysis and International Stereotactic Radiosurgery Society practice guidelines","volume":"182","author":"Yan","year":"2023","journal-title":"Lung Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","article-title":"Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"26","author":"Heinzerling","year":"2025","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20240510-00189","article-title":"Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)","volume":"46","author":"Han","year":"2024","journal-title":"Chin J Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70104","article-title":"Effect of cancer cachexia on the efficacy and treatment delivery of chemotherapy in older patients with advanced small cell lung cancer","volume":"16","author":"Yabe","year":"2025","journal-title":"Thorac Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/bjr\/tqaf133","article-title":"Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer: predictors and effect on survival","volume":"98","author":"Appel","year":"2025","journal-title":"Br J Radiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115341","article-title":"Blocking the functional domain of TIP1 by antibodies sensitizes cancer to radiation therapy","volume":"166","author":"Singh","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.703893","article-title":"Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer","volume":"11","author":"Daniello","year":"2021","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.hoc.2023.02.002","article-title":"Nonsurgical therapy for early-stage lung cancer","volume":"37","author":"Daly","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"B21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40644-022-00491-1","article-title":"CT patterns and serial CT changes in lung cancer patients post stereotactic body radiotherapy (SBRT)","volume":"22","author":"Al-Umairi","year":"2022","journal-title":"Cancer Imaging"},{"key":"B22","first-page":"63","article-title":"Safety and efficacy of stereotactic body proton therapy for high-risk lung tumors","volume":"9","author":"McMillan","year":"2023","journal-title":"J Radiosurg SBRT"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110529","article-title":"Brachial plexopathy following stereotactic body radiation therapy in apical lung Malignancies: a dosimetric pooled analysis of individual patient data","volume":"200","author":"Bai","year":"2024","journal-title":"Radiother Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12885-021-07923-4","article-title":"Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment","volume":"21","author":"Wong","year":"2021","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.03.050","article-title":"Stereotactic radiation for ultra-central non-small cell lung cancer: a safety and efficacy trial (SUNSET)","volume":"120","author":"Giuliani","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2025.101015","article-title":"A retrospective analysis of the efficacy and safety of immune combination therapy in driver gene-negative non-small cell lung cancer with brain metastases","volume":"45","author":"Li","year":"2025","journal-title":"Cancer Treat Res Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12916-022-02245-z","article-title":"Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.07.1818","article-title":"Prospective evaluation of non-small cell lung cancer radiation therapy treatment interruptions in a large statewide quality collaborative","volume":"120","author":"Elaimy","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110014","article-title":"Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: a systematic review and meta-analysis","volume":"190","author":"Feng","year":"2024","journal-title":"Radiother Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70051","article-title":"Stereotactic body radiotherapy plus cadonilimab (PD-1\/CTLA-4 bispecific antibody) as third-line or beyond therapy for refractory solid tumors: a phase 1b study","volume":"45","author":"Xiao","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.64229\/v6s2ft48","article-title":"Frontiers in cancer and haematology: emerging biomarkers, therapeutics, and technologies","volume":"1","author":"Yousafzai","year":"2025","journal-title":"Curr Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2476729","article-title":"Association of anti-PD-(L)1 treatment duration to efficacy in advanced solid tumors: a single center retrospective study","volume":"57","author":"Kuusisalo","year":"2025","journal-title":"Ann Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s12885-023-10979-z","article-title":"Circulating tumor cells (CTCs) and hTERT gene expression in CTCs for radiotherapy effect with lung cancer","volume":"23","author":"Xu","year":"2023","journal-title":"BMC Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1005876","article-title":"Iodine-125 brachytherapy treatment for newly diagnosed brain metastasis in non-small cell lung cancer: a biocentric analysis","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/onco6010008","article-title":"Impact of unplanned radiotherapy interruptions and prolonged overall treatment time on recurrence in head and neck squamous-cell carcinoma: a retrospective analysis from a single institution","volume":"6","author":"Angiras","year":"2026","journal-title":"Onco"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30090611","article-title":"Durvalumab treatment patterns for patients with unresectable stage III non-small cell lung cancer in the Veterans Health Administration (VHA): a nationwide, real-world study","volume":"30","author":"Moore","year":"2023","journal-title":"Curr Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.06.3637","article-title":"Treatment interruptions in NSCLC radiotherapy: impact on outcomes in a statewide quality collaborative","volume":"123","author":"Elaimy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1894291\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:36Z","timestamp":1788150576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1894291\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":37,"alternative-id":["10.3389\/fonc.2026.1894291"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1894291","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1894291"}}